NO172168C - Fremgangsmaate for fremstilling av faste nifedipinpreparater med hoey biotilgjengelighet og med forlenget virkning - Google Patents

Fremgangsmaate for fremstilling av faste nifedipinpreparater med hoey biotilgjengelighet og med forlenget virkning

Info

Publication number
NO172168C
NO172168C NO864060A NO864060A NO172168C NO 172168 C NO172168 C NO 172168C NO 864060 A NO864060 A NO 864060A NO 864060 A NO864060 A NO 864060A NO 172168 C NO172168 C NO 172168C
Authority
NO
Norway
Prior art keywords
polyethylene glycol
active substance
solution
micronized
bios
Prior art date
Application number
NO864060A
Other languages
English (en)
Norwegian (no)
Other versions
NO172168B (no
NO864060L (no
NO864060D0 (no
Inventor
Massimo Calanchi
Piergiorgio Rossi
Original Assignee
Eurand Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Int filed Critical Eurand Int
Publication of NO864060D0 publication Critical patent/NO864060D0/no
Publication of NO864060L publication Critical patent/NO864060L/no
Publication of NO172168B publication Critical patent/NO172168B/no
Publication of NO172168C publication Critical patent/NO172168C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
NO864060A 1985-10-15 1986-10-13 Fremgangsmaate for fremstilling av faste nifedipinpreparater med hoey biotilgjengelighet og med forlenget virkning NO172168C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22494/85A IT1187751B (it) 1985-10-15 1985-10-15 Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute

Publications (4)

Publication Number Publication Date
NO864060D0 NO864060D0 (no) 1986-10-13
NO864060L NO864060L (no) 1987-04-21
NO172168B NO172168B (no) 1993-03-08
NO172168C true NO172168C (no) 1993-06-16

Family

ID=11197023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO864060A NO172168C (no) 1985-10-15 1986-10-13 Fremgangsmaate for fremstilling av faste nifedipinpreparater med hoey biotilgjengelighet og med forlenget virkning

Country Status (18)

Country Link
US (1) US4880623A (ko)
EP (1) EP0220760B1 (ko)
JP (1) JPH0811731B2 (ko)
KR (1) KR940006320B1 (ko)
AT (1) ATE66367T1 (ko)
AU (1) AU590622B2 (ko)
CA (1) CA1280976C (ko)
DE (1) DE3680989D1 (ko)
DK (1) DK168691B1 (ko)
ES (1) ES2040209T3 (ko)
FI (1) FI87424C (ko)
GR (1) GR3003150T3 (ko)
HK (1) HK12595A (ko)
IT (1) IT1187751B (ko)
NO (1) NO172168C (ko)
NZ (1) NZ217841A (ko)
PT (1) PT83522B (ko)
ZA (1) ZA867767B (ko)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5215752A (en) * 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US5028433A (en) * 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) * 1990-11-20 1991-01-02 Solomon Montague C Nifedipine dosage forms
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
DK0557244T3 (da) * 1992-02-17 1996-04-01 Siegfried Ag Pharma Dosisformer med forlænget afgivelse af aktivt stof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
WO1994005262A1 (en) * 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
ES2322405T3 (es) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CA2511992A1 (en) * 2003-02-24 2004-09-10 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
DE04758472T1 (de) * 2003-03-26 2005-06-23 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung eines pharmazeutischen wirkstoffs mit hochspezifischer oberfläche
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
TW200804309A (en) * 2006-02-28 2008-01-16 Helicon Therapeutics Inc Therapeutic piperazines
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
RU2629843C1 (ru) * 2016-05-24 2017-09-04 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Способ получения мази нифедипина (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO98434A (ko) * 1959-04-30
US3988439A (en) * 1973-11-05 1976-10-26 Eli Lilly And Company Dibenzo[b,d]pyranone dispersions
US3920809A (en) * 1973-11-05 1975-11-18 Lilly Co Eli Dibenzo(b,d)pyranone dispersions
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
NO172168B (no) 1993-03-08
IT1187751B (it) 1987-12-23
FI87424B (fi) 1992-09-30
IT8522494A0 (it) 1985-10-15
EP0220760B1 (en) 1991-08-21
NO864060L (no) 1987-04-21
EP0220760A2 (en) 1987-05-06
FI87424C (fi) 1993-01-11
DE3680989D1 (de) 1991-09-26
JPS62167727A (ja) 1987-07-24
PT83522B (pt) 1988-11-30
US4880623A (en) 1989-11-14
DK168691B1 (da) 1994-05-24
AU6383286A (en) 1987-04-16
CA1280976C (en) 1991-03-05
FI864151A0 (fi) 1986-10-14
ATE66367T1 (de) 1991-09-15
FI864151A (fi) 1987-04-16
ZA867767B (en) 1987-06-24
PT83522A (en) 1986-11-01
ES2040209T3 (es) 1993-10-16
KR940006320B1 (ko) 1994-07-16
DK481186A (da) 1987-04-16
HK12595A (en) 1995-02-03
AU590622B2 (en) 1989-11-09
DK481186D0 (da) 1986-10-08
NZ217841A (en) 1990-01-29
EP0220760A3 (en) 1987-09-23
JPH0811731B2 (ja) 1996-02-07
KR870003779A (ko) 1987-05-04
GR3003150T3 (en) 1993-02-17
NO864060D0 (no) 1986-10-13

Similar Documents

Publication Publication Date Title
NO172168C (no) Fremgangsmaate for fremstilling av faste nifedipinpreparater med hoey biotilgjengelighet og med forlenget virkning
CA1329543C (en) Human growth hormone formulation
JP4615633B2 (ja) 局所薬剤デリバリのためのゲル調合物
EP1175205B1 (en) Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
AU685784B2 (en) Excipient stabilization of polypeptides treated with organic solvents
CA1069047A (en) Process for preparing preparations for oral administration
ES2077897T3 (es) Preparados farmaceuticos secos de dosis bajas.
NO863796D0 (no) Fremgangsmaate for fremstilling av farmakologiske preparater med forlenget virkningstiden.
De Smidt et al. Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes
BG64664B1 (bg) Нимезулидни гел системи за локално приложение
JPS5781409A (en) External plaster
NOMURA et al. Percutaneous absorption of indomethacin from mixtures of fatty alcohol and propylene glycol (FAPG bases) through rat skin: effects of oleic acid added to FAPG base
JP2516524B2 (ja) 持続性製剤
Dorr et al. Preclinical pharmacokinetics and antitumor activity of imexon
JP3202775B2 (ja) 固形製剤
Wisudyaningsih et al. IAI SPECIAL EDITION: Effect of gelling agent and penetration enhancer on the release rate of ibuprofen-PEG 6000 solid dispersion from gel preparations
JPH021403A (ja) 医薬組成物
Shiu et al. The effect of food on the absorption of controlled-release theophylline in mini-swine
WO2015149144A2 (en) Stabilization of factor viii without calcium as an excipient
Wisudyaningsih et al. IMPROVEMENT ON IN-VITRO EFFECTIVITY OF IBUPROFEN SOLID DISPERSION ON TRANSDERMAL PATCH FORMULATION
DE19548367A1 (de) Immunologisch wirksame Mistelextraktzubereitungen
Sincholle et al. Corneal penetration and metabolism of the antiherpetic 5-iodo-2′-deoxycytidine
JPH02196721A (ja) 抗癌剤
JPH0193527A (ja) 医薬組成物